World's second stem cell drug will be approved for production

The South Korean Food and Drugs Agency said on January 8 that the production license of Medi-post's Cartistem and Anterogen's anorectal treatment drug, Cupepistem, will be approved in the middle of this month.

Hearticellgram-AMI, the world's first stem cell drug for the treatment of coronary heart disease, produced by a Korean pharmaceutical company has been approved for production in Korea. The two drugs that will be approved for production this time are the world's second stem cell therapeutics.

Responsible individuals from Medi-post and Anterogen said that they had completed the review of the project and were convinced that they could obtain a production license from the Korean government.

Medi-post's Cartistem is a drug that is specially developed to treat degenerative arthritis and damaged knee cartilage using stem cells extracted from umbilical cord blood.

It is worth noting that instead of using the patient's own stem cells, Cartistem uses the stem cells of others, so if the production permit is obtained, it will become the world's first therapeutic drug produced using stem cells from other people.

Anterogen's Cuepistem is a drug used to treat complex cloning-enzootic anal fistula made from stem cells extracted from the patient's own adipose tissue. Anterogen is currently mastering the original technology of adipose stem cells and is also one of the first companies in South Korea to conduct stem cell research.

According to the public information of the Korean government and related companies, if Cartistem and Cuepistem get a production license, they can enter the Korean market within one month to two months.